Pharmaceutical News

RSS

Biovail acquires worldwide rights to Tetrabenazine

Biovail Corporation today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine tablets), and the associated intellectual property rights held by Cambridge Laboratories (Ireland) Ltd and its affiliates.

18 May 2009

A.P. Pharma submits NDA for APF530 in chemo-induced nausea and vomiting

A.P. Pharma, Inc. has announced that it has submitted a New Drug Application (NDA) for its lead product, APF530, to the U.S. Food and Drug Administration (FDA). APF530 is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer drug delivery system.

18 May 2009

Rituximab linked to viral brain infection

The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares.

18 May 2009

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

18 May 2009

Onyx Pharmaceuticals files complaint against Bayer on fluoro-sorafenib

Onyx Pharmaceuticals, Inc. today announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights to a Phase 2 anti-cancer compound discovered during joint research between Onyx and Bayer.

17 May 2009

Washington State drops budget provision that would have cut Medicaid pharmacy payments

Washington state lawmakers this week eliminated a budgetary proposal that would have reduced Medicaid payment rates to pharmacies to the lowest levels in the country, the AP/Spokane Spokesman-Review reports.

15 May 2009

Pfizer to give away 70 of its most widely prescribed drugs to those who lost jobs

Pfizer on Thursday announced a new program that would provide some of its existing customers access to more than 70 types of medications at no cost if they have recently been laid off or lost their prescription drug coverage, USA Today reports. The program -- called MAINTAIN, or Medicines Assistance for Those who Are in Need -- will begin July 1.

15 May 2009

Morphine patches create addiction

Morphine patches are supposed to reduce use of painkillers, and provide more control over their use in chronic pain conditions. But researchers at the Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital in Trondheim have found otherwise.

15 May 2009

Prescription drug use dropped in 2008, though spending increased, Medco Research indicates

Use of prescription drugs in the U.S. declined in 2008 -- the first such decrease in a decade -- but total spending on such treatments increased by 3.3%, according to a report released on Wednesday by Medco Health Solutions, the AP/Washington Post reports.

14 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

Baylor Research Institute receives multi-million dollar grant to develop flu vaccine

Scientists at Baylor Institute for Immunology Research (BIIR) in Dallas, part of Baylor Research Institute (BRI) and the Baylor Health Care System, announced today that they received a renewal of a multi-million dollar grant from the National Institutes of Health (NIH) to design new vaccines to prevent influenza - including swine flu (H1N1).

13 May 2009

FDA accepts Pharmaxis’ Aridol NDA for review

Pharmaxis has announced it had received notification from the United States Food and Drug Administration (FDA) that the New Drug Application (NDA) for its mannitol bronchial challenge test Aridol has been accepted for standard review. The FDA will advise the result of the review on 27 December 2009.

13 May 2009

Independent pharmacists raise concerns over letters from CVS Caremark indicating members must pay higher copayments at non-CVS pharmacies

An unidentified trade group representing independent pharmacies on Wednesday plans to send to Federal Trade Commission Chair Jon Leibowitz a series of letters from pharmacy benefits manager CVS Caremark that indicate the PBM charges higher copayment rates for some of its members who opt to fill their prescriptions at pharmacies other than CVS, the Wall Street Journal reports.

13 May 2009

GlaxoSmithKline to acquire 16% shareholding in Aspen Pharmacare

GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company.

12 May 2009

Sinobiopharma announces Chinese approval of Perindopril

Sinobiopharma, Inc. has announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its formulation of Perindopril, an anti-hypertension drug.

12 May 2009

Sanofi-aventis to acquire Oforta, oral chronic lymphocytic leukemia treatment

Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

12 May 2009

FDA approves Samsca tablets (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

8 May 2009

FDA approves Besivance for the treatment of bacterial conjunctivitis

The U.S. Food and Drug Administration has approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.

8 May 2009

FDA approves Avastin (bevacizumab) for treatment of glioblastoma multiforme

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standard therapy.

7 May 2009

Study reveals current multi-component vaccines may need reworking

Current strategies for designing vaccines against HIV and cancers, for instance, may enable some components in multi-component vaccines to cancel the effect of others on the immune system, eliminating their ability to provide protection, according to an article to be published shortly in the Proceedings of the National Academy of Sciences (PNAS).

7 May 2009